Prognostic factors and survival

Sjogren's Syndrome: Diagnosis and Therapeutics

Volumn , Issue , 2012, Pages 493-499

  Goules, Andreas V ^a   Skopouli, Fotini N ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HAROKOPIO UNIVERSITY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84948097388     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-85729-947-5_34     Document Type: Chapter

References (34)

1. Moutsopoulos HM. Sjogren’s syndrome: autoimmune epithelitis. Clin Immunol Immunopathol. 1994;72:162-5.
2. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjogren’s syndrome. Semin Arthritis Rheum. 2000;29:296-304.
3. Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren’s syndrome. Arthritis Rheum. 1996;39:767-72.
4. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjogren’s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren’s syndrome. Arthritis Rheum. 1999;42:1765-72.
5. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren’s syndrome. Arthritis Rheum. 2002;46:741-7.
6. Voulgarelis M, Giannouli S, Anagnostou D, Tzioufas AG. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjogren’s syndrome-associated B-cell aggressive non-Hodgkin’s lymphomas. Rheumatology (Oxford). 2004;43:1050-3.
7. Voulgarelis M, Giannouli S, Tzioufas AG, Moutsopoulos HM. Long term remission of Sjogren’s syndrome associated aggressive B cell non-Hodgkin’s lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis. 2006;65:1033-7.
8. Voulgarelis M, Moutsopoulos HM. Mucosa-associated lymphoid tissue lymphoma in Sjögren’s syndrome: risks, management, and prognosis. Rheum Dis Clin North Am. 2008;34:921-33, viii.
9. Rothman S, Block M, Hauser FV. Sjogren’s syndrome associated with lymphoblastoma and hypersplenism. AMA Arch Derm Syphilol. 1951;63:642-3.
10. Talal N, Bunim JJ. The development of malignant lymphoma in the course of Sjogren’s syndrome. Am J Med. 1964;36:529-40.
11. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978;89:888-92.
12. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165:2337-44.
13. Kauppi M, Pukkala E, Isomaki H. Elevated incidence of hematologic malignancies in patients with Sjogren’s syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control. 1997;8:201-4.
14. Pariente D, Anaya JM, Combe B, Jorgensen C, Emberger JM, Rossi JF, et al. Non-Hodgkin’s lymphoma associated with primary Sjogren’s syndrome. Eur J Med. 1992;1:337-42.
15. Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore). 2009;88:284-93.
16. Mariette X. Lymphomas in patients with Sjogren’s syndrome: review of the literature and physiopathologic hypothesis. Leuk Lymphoma. 1999;33:93-9.
17. Royer B, Cazals-Hatem D, Sibilia J, Agbalika F, Cayuela JM, Soussi T, et al. Lymphomas in patients with Sjogren’s syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood. 1997;90:766-75.
18. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjogren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65:796-803.
19. Ambrosetti A, Zanotti R, Pattaro C, Lenzi L, Chilosi M, Caramaschi P, et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjogren syndrome or hepatitis C virus infection. Br J Haematol. 2004;126:43-9.
20. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
21. Kruize AA, Hene RJ, van der Heide A, Bodeutsch C, de Wilde PC, van Bijsterveld OP, et al. Long-term followup of patients with Sjogren’s syndrome. Arthritis Rheum. 1996;39:297-303.
22. Martens PB, Pillemer SR, Jacobsson LT, O’Fallon WM, Matteson EL. Survivorship in a population based cohort of patients with Sjogren’s syndrome, 1976-1992. J Rheumatol. 1999;26:1296-300.
23. Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A. A longitudinal cohort study of Finnish patients with primary Sjogren’s syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis. 2001;60:467-72.
24. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjogren’s syndrome: a prospective cohort study. Arthritis Rheum. 2004;50:1262-9.
25. Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos AA. Epidemiology of primary Sjogren’s syndrome in north-west Greece, 1982-2003. Rheumatology (Oxford). 2006;45:187-91.
26. Brito-Zeron P, Ramos-Casals M, Bove A, Sentis J, Font J. Predicting adverse outcomes in primary Sjogren’s syndrome: identification of prognostic factors. Rheumatology (Oxford). 2007;46:1359-62.
27. Goules A, Masouridi S, Tzioufas AG, Ioannidis JP, Skopouli FN, Moutsopoulos HM. Clinically significant and biopsy-documented renal involvement in primary Sjogren syndrome. Medicine (Baltimore). 2000;79:241-9.
28. Aygen B, Dursun FE, Dogukan A, Ozercan IH, Celiker H. Hypokalemic quadriparesis associated with renal tubular acidosis in a patient with Sjogren’s syndrome. Clin Nephrol. 2008;69:306-9.
29. Dowd JE, Lipsky PE. Sjogren’s syndrome presenting as hypokalemic periodic paralysis. Arthritis Rheum. 1993;36:1735-8.
30. Zimhony O, Sthoeger Z, Ben David D, Bar Khayim Y, Geltner D. Sjogren’s syndrome presenting as hypokalemic paralysis due to distal renal tubular acidosis. J Rheumatol. 1995;22: 2366-8.
31. Tsokos M, Lazarou SA, Moutsopoulos HM. Vasculitis in primary Sjogren’s syndrome. Histologic classification and clinical presentation. Am J Clin Pathol. 1987;88:26-31.
32. Anderson LG, Talal N. The spectrum of benign to malignant lymphoproliferation in Sjogren’s syndrome. Clin Exp Immunol. 1972;10:199-221.
33. Tzioufas AG, Costello R, Manoussakis MN, Papadopoulos NM, Moutsopoulos HM. Cryoglobulinemia in primary Sjogren’s syndrome: a monoclonal process. Scand J Rheumatol Suppl. 1986;61:111-3.
34. Ramos-Casals M, Brito-Zeron P, Yague J, Akasbi M, Bautista R, Ruano M, et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren’s syndrome. Rheumatology (Oxford). 2005;44:89-94.